Literature DB >> 10987842

The effects of methamphetamine on serotonin transporter activity: role of dopamine and hyperthermia.

H M Haughey1, A E Fleckenstein, R R Metzger, G R Hanson.   

Abstract

Multiple administrations of methamphetamine (METH) rapidly decreased serotonin (5HT) transporter (SERT) function in rat striatum and hippocampus. The purpose of this study was to identify the mechanisms/ factors contributing to this METH-induced decrease in SERT function. Multiple high-dose METH injections rapidly decreased 5HT uptake without altering binding of the 5HT transporter ligand paroxetine. Hyperthermia contributed to this deficit in transporter function in striatum and hippocampus, as prevention of METH-induced hyperthermia attenuated this decrease. A role for dopamine (DA) was suggested by findings that pretreatment with the tyrosine hydroxylase inhibitor alpha-methyl-p-tyrosine, the D1 antagonist SCH-23390, or the D2 antagonist eticlopride attenuated the METH-induced decrease in striatal, but not hippocampal, SERT activity. These effects were independent of the ability of these DA-antagonizing drugs to prevent METH-induced hyperthermia. These results suggest that DA contributes to the decrease in SERT function caused by multiple METH injections in the striatum, but not hippocampus, and that hyperthermia facilitates these deficits in SERT function in both brain regions. In contrast, the response of SERT to a single administration of METH was DA and hyperthermia independent. These findings suggest that the mechanisms/ factors involved in decreasing SERT activity after a single administration of METH are distinct from that caused by multiple administrations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10987842     DOI: 10.1046/j.1471-4159.2000.0751608.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  20 in total

1.  Prior methamphetamine self-administration attenuates serotonergic deficits induced by subsequent high-dose methamphetamine administrations.

Authors:  Lisa M McFadden; Madison M Hunt; Paula L Vieira-Brock; Janice Muehle; Shannon M Nielsen; Scott C Allen; Glen R Hanson; Annette E Fleckenstein
Journal:  Drug Alcohol Depend       Date:  2012-05-28       Impact factor: 4.492

2.  Dopamine D(3) receptors contribute to methamphetamine-induced alterations in dopaminergic neuronal function: role of hyperthermia.

Authors:  Michelle G Baladi; Amy H Newman; Shannon M Nielsen; Glen R Hanson; Annette E Fleckenstein
Journal:  Eur J Pharmacol       Date:  2014-03-28       Impact factor: 4.432

3.  4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse.

Authors:  Gregory C Hadlock; Katy M Webb; Lisa M McFadden; Pei Wen Chu; Jonathan D Ellis; Scott C Allen; David M Andrenyak; Paula L Vieira-Brock; Christopher L German; Kevin M Conrad; Amanda J Hoonakker; James W Gibb; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2011-08-02       Impact factor: 4.030

4.  Prior methamphetamine self-administration attenuates the dopaminergic deficits caused by a subsequent methamphetamine exposure.

Authors:  Lisa M McFadden; Paula L Vieira-Brock; Glen R Hanson; Annette E Fleckenstein
Journal:  Neuropharmacology       Date:  2015-01-31       Impact factor: 5.250

5.  A Mutation in Hnrnph1 That Decreases Methamphetamine-Induced Reinforcement, Reward, and Dopamine Release and Increases Synaptosomal hnRNP H and Mitochondrial Proteins.

Authors:  Qiu T Ruan; Neema Yazdani; Benjamin C Blum; Jacob A Beierle; Weiwei Lin; Michal A Coelho; Elissa K Fultz; Aidan F Healy; John R Shahin; Amarpreet K Kandola; Kimberly P Luttik; Karen Zheng; Nathaniel J Smith; Justin Cheung; Farzad Mortazavi; Daniel J Apicco; Durairaj Ragu Varman; Sammanda Ramamoorthy; Peter E A Ash; Douglas L Rosene; Andrew Emili; Benjamin Wolozin; Karen K Szumlinski; Camron D Bryant
Journal:  J Neurosci       Date:  2019-11-08       Impact factor: 6.167

6.  Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model.

Authors:  V Sandoval; E L Riddle; Y V Ugarte; G R Hanson; A E Fleckenstein
Journal:  J Neurosci       Date:  2001-02-15       Impact factor: 6.167

7.  Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure.

Authors:  Lisa M McFadden; Greg C Hadlock; Scott C Allen; Paula L Vieira-Brock; Kristen A Stout; Jonathan D Ellis; Amanda J Hoonakker; David M Andrenyak; Shannon M Nielsen; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2011-10-27       Impact factor: 4.030

8.  Work aversion and associated changes in dopamine and serotonin transporter after methamphetamine exposure in rats.

Authors:  Alisa R Kosheleff; Millie Grimes; Steve J O'Dell; John F Marshall; Alicia Izquierdo
Journal:  Psychopharmacology (Berl)       Date:  2011-06-04       Impact factor: 4.530

9.  Comparison of (+)-methamphetamine, ±-methylenedioxymethamphetamine, (+)-amphetamine and ±-fenfluramine in rats on egocentric learning in the Cincinnati water maze.

Authors:  Charles V Vorhees; Elizabeth He; Matthew R Skelton; Devon L Graham; Tori L Schaefer; Curtis E Grace; Amanda A Braun; Robyn Amos-Kroohs; Michael T Williams
Journal:  Synapse       Date:  2010-10-08       Impact factor: 2.562

10.  Extended methamphetamine self-administration in rats results in a selective reduction of dopamine transporter levels in the prefrontal cortex and dorsal striatum not accompanied by marked monoaminergic depletion.

Authors:  Marek Schwendt; Angelica Rocha; Ronald E See; Alejandra M Pacchioni; Jacqueline F McGinty; Peter W Kalivas
Journal:  J Pharmacol Exp Ther       Date:  2009-07-31       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.